ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Astria Therapeutics to Present at Upcoming Investor Conferences

September 10, 2021 GMT

BOSTON--(BUSINESS WIRE)--Sep 10, 2021--

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the following upcoming virtual investor conferences:

ADVERTISEMENT

Webcasts of the events can be accessed from the investors section of www.astriatx.com. Archived replays will be available for 30 days following the event.

About Astria Therapeutics:

ADVERTISEMENT

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210910005022/en/

CONTACT: Astria:

Investor relations:

Andrea Matthews

investors@astriatx.com

Media:

Elizabeth Higgins

media@astriatx.com

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CARDIOLOGY

SOURCE: Astria Therapeutics, Inc.

Copyright Business Wire 2021.

PUB: 09/10/2021 08:00 AM/DISC: 09/10/2021 08:02 AM

http://www.businesswire.com/news/home/20210910005022/en